Simplified global trading solutions designed for speed, transparency.
↳
With deep industry expertise and a strong global network, we manage sourcing, logistics, and compliance with precision.
Blogs
Explore insights, trends, and ideas in branding, marketing, design, and digital growth. Stay updated with practical strategies, creative inspiration, and industry knowledge to help your business grow smarter and stronger.
19.06.2026 Insights
Why International Buyers Prefer Indian Generic Medicines for Bulk Import
Walk into a pharmacy in Nairobi, a hospital dispensary in Riyadh, or a wholesale distribution centre in Kuala Lumpur, and the odds are good that a meaningful share of the stock came from India. This is not a coincidence. International buyers making bulk procurement decisions keep returning to Indian generic medicines for a set of concrete, well-documented reasons: price, regulatory credibility, product range, and supply reliability.
Let’s break it down.
The Scale Behind the Preference
India’s pharmaceutical sector is the world’s single largest source of generic medicines by volume. The country accounts for 20% of global generic drug exports by volume and ships pharmaceutical products to more than 200 countries. In FY 2024-25, India’s total pharmaceutical exports crossed USD 30.47 billion, a 9.4% increase over the previous year, according to the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) and the Indian Ministry of Commerce.
That figure reflects consistent demand from international buyers who made purchasing decisions based on real-world performance, not marketing claims. Here is why those buyers keep coming back.
Reason 1: Price That Works for Real Procurement Budgets
The most straightforward reason international buyers source Indian generic medicines for bulk import is price. Indian manufacturers produce generic drugs at costs that are structurally lower than equivalents from North America or Western Europe, and the gap is large enough to matter at scale.
The cost advantage comes from several compounding factors: a large pool of trained pharmaceutical graduates that keeps labour costs in check, a well-developed domestic chemical industry that supplies raw material inputs, and a generic drug model that carries no research and development recovery costs built into the price.
The savings for bulk buyers are real. Studies on generic chemotherapy drugs manufactured in India found that Indian generics cost between 8.9% and 36% of the equivalent branded originator product, generating savings of hundreds to thousands of dollars per treatment cycle. India’s Jan Aushadhi programme also reports its generic medicines are priced up to 80% below branded equivalents for the same molecules, reflecting the underlying cost structure that benefits international buyers sourcing in bulk.
Reason 2: Regulatory Compliance That Opens Doors in Regulated Markets
Price alone would not be enough if the medicines failed quality checks at destination ports. Indian generic medicines for bulk import clear those checks consistently because Indian manufacturers have built compliance infrastructure that meets the standards of the world’s most demanding regulatory agencies.
Here is the compliance picture by the numbers:
- India has over 262 US FDA-compliant manufacturing plants, the highest count of any country outside the United States.
- India has approximately 1,400 WHO-GMP-approved manufacturing facilities.
- India has 253 EDQM (European Directorate for the Quality of Medicines and Healthcare)-approved plants, enabling supply into European markets.
Each approval requires a physical inspection of the facility, data integrity audits, and ongoing compliance monitoring. For international buyers, this matters in two practical ways. First, it means the product clears customs and regulatory review in the destination country without rejection or delay. Second, it gives buyers a verifiable quality signal to present to their own customers, whether those are hospitals, health ministries, or retail pharmacy chains.
WHO-GMP certification is the gateway to public health procurement. Buyers supplying medicines to programmes run by UNICEF or government health ministries typically require WHO-GMP certification from the source manufacturer. India’s 1,400-facility WHO-GMP base gives buyers a wide and verified pool to draw from.
Reason 3: Product Range That Covers Most Therapeutic Needs
A bulk buyer sourcing across multiple therapeutic categories has a practical preference for suppliers who can cover a wide range. Fewer supplier relationships means fewer compliance reviews and fewer freight arrangements to coordinate.
India’s generic drug manufacturing base covers nearly every major therapeutic category, including antibiotics, analgesics, anti-inflammatory drugs, antihypertensives, antiretrovirals, oncology drugs, vaccines, and diabetes treatments. Formulations and biologics account for 79.26% of India’s total pharmaceutical exports by value, with bulk drugs and drug intermediates making up 16.08%.
India manufactures over 500 different APIs and holds a 57% share of all APIs on the WHO prequalified list. For buyers who manufacture their own formulations, sourcing upstream inputs and finished products from the same country through a single trading relationship is entirely feasible, and often the most cost-effective approach.
Reason 4: A Manufacturing Base Backed by Government Investment
International buyers think about supply security, not just the next shipment. India’s government has committed real capital to expanding pharmaceutical manufacturing capacity and reducing raw material import dependence.
The Production Linked Incentive (PLI) Scheme for Bulk Drugs, with a total outlay of Rs. 6,940 crore running through FY 2029-30, targets domestic manufacturing of 41 identified APIs and key starting materials. As of September 2025, capacity had been created for 26 APIs with cumulative sales of Rs. 2,315 crore. The PLI Scheme for Pharmaceuticals, with a Rs. 15,000 crore outlay through FY 2027-28, supports 55 manufacturers producing biopharmaceuticals, complex generics, and oncology drugs. Three dedicated Bulk Drug Parks in Andhra Pradesh, Gujarat, and Himachal Pradesh provide shared infrastructure for API manufacturing.
For bulk buyers, this government commitment translates to a supplier base expanding its capacity and reducing single-source supply risk. That is supply security built into the system.
Reason 5: Documentation and Logistics That Reduce Friction
Bulk pharmaceutical import is paperwork-intensive. Documentation requirements include certificates of analysis, certificates of origin, product registration documents, manufacturing licences, and country-specific compliance paperwork that varies by destination market.
Indian exporters and trading partners have built real experience managing this documentation across markets as diverse as the US, UK, GCC, and Southeast Asia. That experience reduces delays at customs and lowers the risk of shipment rejections that disrupt supply chains.
This is where companies like Srindhya Global serve a concrete function. Operating from Bangalore and serving buyers across the GCC and Southeast Asia, Srindhya Global sources finished pharmaceutical products and pharma raw materials from verified Indian manufacturers and manages the full compliance documentation process for each shipment. Buyers get access to India’s generic medicine manufacturing base without handling the regulatory and logistics complexity themselves.
New Trade Agreements Add a Structural Advantage
Two agreements signed and activated in 2025 have made sourcing Indian generic medicines for bulk import even more attractive for buyers in specific markets.
The India-UK Comprehensive Economic and Trade Agreement (CETA), signed in July 2025, grants zero-tariff access to nearly all Indian pharmaceutical exports entering the UK market. Indian pharmaceutical exports to the UK were already growing at 12.6% year-on-year before the agreement came into force. The India-EFTA Trade and Economic Partnership Agreement, which came into force in October 2025, adds further access to European markets with reduced trade friction.
For buyers in the UK and Europe, these agreements represent a direct cost reduction on the landed price of Indian generic medicines, with no change to the underlying product quality.
What to Look for When Sourcing in Bulk
Not every supplier in India’s pharmaceutical export market will meet your standards. Here is a quick checklist for buyers evaluating sourcing options.
Manufacturer certifications: Confirm the source manufacturer holds the regulatory approvals your destination market requires. WHO-GMP for most markets, US FDA approval for the United States, and EDQM/EU-GMP for European destinations.
Documentation completeness: Ask for a sample documentation package before your first order, covering the certificate of analysis, certificate of origin, and destination-specific compliance documents.
Product registration: Some products require registration with the destination country’s drug authority before import is permitted. Confirm this early, not after the order is placed.
Trading partner due diligence: If you work through a B2B trading company, confirm they verify manufacturer credentials rather than simply pass orders through. Srindhya Global conducts manufacturer verification as a standard part of its sourcing process.
Lead times: Sea freight from Indian ports to GCC destinations typically runs 8-14 days. Routes to Southeast Asia run 10-20 days. Plan buffer stock accordingly.
FAQS
Have a question before getting in touch? Below are the answers to the queries we hear most often from international B2B buyers. If your question is not covered here, send us a message and our trade team will respond within 24 hours.
Indian generic drug manufacturers benefit from lower labour costs, a domestic chemical industry that supplies raw materials competitively, and large-scale manufacturing that keeps per-unit costs down. These structural factors allow Indian manufacturers to price generics well below originator branded products while meeting the same international quality standards.
Ask for the manufacturer's regulatory certificates directly: WHO-GMP approval, US FDA approval if relevant to your market, and EDQM or EU-GMP certificates for European destinations. Each certificate is publicly verifiable through the issuing authority's database. A reputable B2B trading partner provides these proactively without waiting to be asked.
Indian manufacturers cover most major therapeutic categories for bulk export, including antibiotics, analgesics, antihypertensives, antiretrovirals, oncology drugs, anti-diabetics, respiratory medicines, and vaccines. Active pharmaceutical ingredients across more than 500 molecules are also available for buyers who manufacture their own formulations.
A complete shipment should include a certificate of analysis, certificate of origin, manufacturing licence copy, product registration documents for the destination country, and any market-specific compliance certificates required by the importing country's drug regulatory authority. Your trading partner should confirm the full documentation list before the order is placed.
Yes. The India-UK Comprehensive Economic and Trade Agreement, signed in July 2025, grants zero-tariff access to nearly all Indian pharmaceutical exports entering the UK. This removes tariff costs that previously applied to some product categories, making Indian generic medicines more price-competitive for UK buyers on a landed-cost basis.